International Journal of Clinical Oncology · 2019 · 15 citations · 14 references
MedicineOncologyPharmacologyChemotherapyGastrointestinal OncologyMolecular OncologyCancer ImmunotherapyGastrointestinal Cancer PharmacotherapySystemic Therapy For Gastrointestinal Cancers5-Fluorouracil TreatmentClinical Trial Efficacy EvaluationGastric Cancer PharmacotherapyHer2-positive Metastatic DiseaseHuman Epidermal Growth Factor Receptor 2-Targeted TherapyMetastatic Gastric CancerPertuzumab TherapySafety Subgroup Analysis
BACKGROUND: The phase III JACOB trial (NCT01774786) compared the efficacy and safety of pertuzumab and trastuzumab plus chemotherapy with placebo and trastuzumab plus chemotherapy in patients with previously untreated human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric or gastroesophageal junction cancer. We conducted a subgroup analysis in Japanese patients. METHODS: every 24 h for 120 h), every 3 weeks. Continuation of chemotherapy after 6 cycles was at the discretion of the patient and the treating physician. RESULTS: A total of 40 Japanese patients were included in each arm. Median overall survival was 22.0 months (95% confidence interval [CI] 13.8-not evaluable) and 15.6 months (95% CI 9.7-19.2) in the pertuzumab and placebo arms, respectively (hazard ratio [HR] 0.64 [95% CI 0.37-1.10]). Median progression-free survival was 12.4 months (95% CI 6.1-14.1) in the pertuzumab arm and 6.3 months (95% CI 4.3-8.1) in the placebo arm (HR 0.50 [95% CI 0.30-0.82]). Grade ≥ 3 adverse events and serious adverse events were more frequent in the pertuzumab arm than the placebo arm. CONCLUSIONS: Results from this subgroup analysis of the JACOB trial suggest similar efficacy of pertuzumab in Japanese patients and patients in the overall population, encouraging continued investigation of new agents for gastric cancer in Japanese patients.
14
Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +12
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Gastric Cancer · 2016 · 2.5K citations · Full text
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elizabeth Smyth, Marcel Verheij, William Allum et al. · Annals of Oncology · 2016 · 1.6K citations